Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesChange in TaxesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Agios Pharmaceuticals (AGIO) Change in Receivables (2016 - 2025)

Agios Pharmaceuticals (AGIO) has disclosed Change in Receivables for 8 consecutive years, with $5.5 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Change in Receivables rose 459.84% year-over-year to $5.5 million, compared with a TTM value of $6.5 million through Dec 2025, up 397.92%, and an annual FY2025 reading of $6.5 million, up 397.92% over the prior year.
  • Change in Receivables was $5.5 million for Q4 2025 at Agios Pharmaceuticals, up from $43000.0 in the prior quarter.
  • Across five years, Change in Receivables topped out at $8.1 million in Q2 2021 and bottomed at -$7.0 million in Q4 2021.
  • Average Change in Receivables over 5 years is $556684.2, with a median of $473000.0 recorded in 2023.
  • Peak annual rise in Change in Receivables hit 459.84% in 2025, while the deepest fall reached 218.97% in 2025.
  • Year by year, Change in Receivables stood at -$7.0 million in 2021, then soared by 140.2% to $2.8 million in 2022, then plummeted by 41.85% to $1.6 million in 2023, then plummeted by 39.35% to $991000.0 in 2024, then surged by 459.84% to $5.5 million in 2025.
  • Business Quant data shows Change in Receivables for AGIO at $5.5 million in Q4 2025, $43000.0 in Q3 2025, and $1.6 million in Q2 2025.